Alzheimer’s Disease: Why One Company Refuses to Give Up the Search for a Cure

It's the sixth leading cause of death in the United States, with no existing cure. But these researchers are committed to finding better ways to diagnose, treat and prevent the debilitating disease, using everything from innovative biomarker tracking to a potential vaccine for early stage patients.

Finding a treatment that can halt Alzheimer’s disease—or even one that can slow its progression—can’t come soon enough.

An estimated 5.3 million people over the age of 65 are living with the disease in the United States, where it’s the sixth leading cause of death. By 2050, that number is expected to more than double, to 13.8 million—one consequence of the fact that, by 2034, those 65 and older will outnumber Americans under 18 for the first time in the nation's history.

It’s sobering statistics like these that help explain why Johnson & Johnson has remained steadfastly committed to battling Alzheimer’s, a degenerative brain condition that can lead to memory loss and other forms of cognitive decline.

“Our company Credo states very clearly that we are dedicated to fighting diseases that affect humanity in a substantial way,” says Simon Lovestone, a world-renowned Alzheimer’s expert and the Neurodegeneration Disease Area Lead at Janssen Research & Development, part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Over the past decade, Lovestone and fellow scientists at Janssen have been laying the groundwork—and developing the right partnerships—to help propel truly transformative research for Alzheimer’s and related neurodegenerative conditions.

“We’re at an inflection point now,” Lovestone says. “I believe the next five years will see significant advances in the search for a treatment.”

Lovestone and other experts who are tackling Alzheimer’s from uniquely innovative angles explain why and how the future of treating the disease looks promising.

Click on the main text for more information.

Citation: www.jnj.com

< Older Post

Newer Post >

The Q2 2026 Capability Ledger

by Gary Hunt • 8 July 2026

The Evolution of UK Manufacturing Capability

You're Fired

by Gary Hunt • 3 July 2026

Structural Convergence in Administrative Law: Institutional Pressure, Statutory Authority and Constitutional Equilibrium in Barclays and Trump v. Slaughter

Purchasing Power Parity Capability Report

by Gary Hunt • 28 June 2026

Purchasing Power Parity Capability Report

White Paper on BARCLAYS BANK UK PLC, National Westminster Bank PLC, Vanquis Bank Limited and Santander UK PLC v Financial Ombudsman Service Limited [2026] EWHC 1555 (Admin)

by Gary Hunt • 25 June 2026

Doctrinal Constraint, Institutional Cognition, and Governance Entropy in the Modern Regulatory Environment

Global Competition Between Capital Environments: Environmental Physics, Liquidity Architecture, and Jurisdictional Advantage.

by Gary Hunt • 6 June 2026

Global Competition Between Capital Environments: Environmental Physics, Liquidity Architecture, and Jurisdictional Advantage.

An Application of Capital Environment Theory

by Gary Hunt • 3 June 2026

An Application of Capital Environment Theory

The Banner of Capital and the Capital Environment Foundations of Capital Environment Theory (CET)

by Gary Hunt • 29 May 2026

The Banner of Capital and the Capital Environment Foundations of Capital Environment Theory (CET)

Property, Power, and Jurisdictional Migration: ExxonMobil, the Texas Business Court, and the Structural Evolution of Corporate Governance

by Gary Hunt • 27 May 2026

Property, Power, and Jurisdictional Migration: ExxonMobil, the Texas Business Court, and the Structural Evolution of Corporate Governance

NatWest Group and the Re‑Emergence of the Strategic Bank

by Gary Hunt • 19 May 2026

NatWest Group and the Re‑Emergence of the Strategic Bank

From the Experience Economy to the Capability Economy

by Gary Hunt • 15 May 2026

From the Experience Economy to the Capability Economy